Abstract

Background

Osteomyelitis of the diabetic foot remains a significant complication that may result in the need for amputation. Proximal surgical margin histopathology after limb-sparing amputation could be used to guide antimicrobial duration and prognostic management but remains debatable. Here we evaluate if negative proximal bone margins predict outcomes of diabetic foot osteomyelitis at 1 year.

Methods

A retrospective study assessed adults with diabetes undergoing limb-sparing foot amputations from September 2016 to September 2019. Patients required histopathology confirmation of osteomyelitis, proximal margin histopathology report, and documented electronic medical record follow-up through 12 months. The primary outcome evaluated if no further amputation at the same site was required in the following 12 months.

Results

Of 92 patients, 57 (61.9%) had pathology-confirmed negative margins for osteomyelitis. Patients with negative margins required less frequent subsequent amputations at the same site within 12 months compared to positive margins (86.0% vs 65.7%; P = .003). Antibiotic duration was shorter in patients with negative margins (mean, 18 vs 30 days; P = .001). Negative-margin patients also noted lower rates of readmission at 12 months (26.3% vs 51.4%; P = .015) for site-specific complications. Staphylococcus aureus was more predominant in patients with positive versus negative margins (57.1% vs 29.8%; P = .017).

Conclusions

Negative proximal bone margin by histopathology was associated with lower frequency of further amputations at the index surgical site within 12 months. This group also received shorter courses of antibiotic therapy. It was also associated with lower rates of readmission at 12 months for surgical-site complications. Proximal margin histopathology results potentially can be integrated to guide antimicrobial duration and decrease the frequency of further amputation at the original site.

According to the Centers for Disease Control and Prevention, an estimated 34.3 million people live with diabetes mellitus in the United States alone, with costs for management hovering around $327 billion in 2017 [1, 2]. Complications from diabetes range from cardiovascular, renal, ocular, and neuropathic disease, to infections and death. A major complication from diabetes with associated comorbidity is the development of diabetic foot infections (DFIs). This often presents a formidable challenge in management for healthcare providers both in the ambulatory and inpatient settings. The presentation can range from significant soft tissue infections to deep bone infections, which often require antimicrobial therapy and a multidisciplinary approach with surgical intervention.

Patients presenting with diabetic foot osteomyelitis (DFO) may require both surgical and medical interventions especially with progressive soft tissue and bone disease, or after failed antimicrobial therapy. However, evidence has been limited and with inconsistent findings on the most appropriate treatment of refractory DFI. Some studies have demonstrated that antimicrobial therapy alone without surgical intervention may still be a reasonable approach [3, 4]. Other studies have indicated that a combined surgical and medical approach may have better outcomes [5, 6]. Current guidelines have suggested surgical debridement of infected bone for further treatment and potentially further antimicrobial therapy in the setting of such infections with history of treatment failures. The now-archived Infectious Diseases Society of America guidelines noted that duration of therapy was not well defined and could be influenced by residual disease at the site of resection, along with any remaining soft tissue involvement. Antimicrobial duration after surgical resection could range anywhere from 2–5 days to 4–6 weeks depending on the presence or absence of residual disease either in the soft tissue or to bone at the amputation margins [7]. Current recommendations from the International Working Group on the Diabetic Foot guidelines recommend obtaining a specimen of bone at the resected margin for culture and histopathology to evaluate if there is residual bone disease in order to help guide antimicrobial therapy, but have noted that these recommendations were considered weak with moderate quality of evidence [8]. Multiple studies have further evaluated the prognostic values of proximal resected surgical margins in DFO, but results have been mixed and this recommendation remains unclear in benefit [9, 10].

Historically, the outcomes with histopathologic presence of osteomyelitis at proximal margins have had mixed results regarding outcomes. One recent study by Johnson et al reported that residual osteomyelitis at proximal margins often needed further surgical intervention or even higher mortality [11]. Kowalski et al evaluated residual osteomyelitis of surgical bone resections of DFO and found that positive margins correlated with increased treatment failures [12]. Simpson et al evaluated outcomes of chronic osteomyelitis of the lower extremities and found that necrotic and infected bone removal was the most crucial factor in cure of infection [13]. This is in contrast to other studies that have demonstrated nonsignificant differences in treatment outcome regardless of a negative or positive histopathologic margin [14, 15].

Given the mixed outcomes of evaluating the benefits of resected surgical margins, the primary purpose of this study was to evaluate the potential predictive impact of resected negative surgical proximal bone margins in DFO and the correlation with clinical outcomes at 12 months, specifically the need for further bone amputation at the same site. Furthermore, the study evaluated if margin results could guide shorter duration of antimicrobial therapy at our institution, and if there were differences in outcome with intravenous versus oral therapy. Finally the study also assessed if other risk factors were associated with clinical failure or success at 12 months.

METHODS

This was a descriptive retrospective study at a single-center safety-net county hospital (Riverside University Health System Medical Center, Moreno Valley, California). The study was approved by the institutional review board and granted a waiver for consent due to the retrospective design. We identified records of patients who underwent limb-sparing below-ankle amputations from September 2016 to September 2019 by International Classification of Diseases, Tenth Revision and Current Procedural Terminology codes through the hospital electronic medical record (EMR) database used by our surgical and podiatry services (Supplementary Table 1). Patients were manually screened to confirm a diagnosis of diabetes, and individuals with a pathology report of histopathologically confirmed osteomyelitis were included for study analysis. Only first encounters of DFO were included.

Patient Selection

Inclusion criteria were as follows: (1) age ≥18 years; (2) clinical diagnosis of diabetes mellitus; (3) having undergone limb-sparing, below-ankle amputation; (4) histopathological confirmation of osteomyelitis; and (5) documented follow-up through 12 months available in the EMR for review.

Individuals were excluded if there was inadequate histopathology descriptive assessment of the presence or absence of osteomyelitis at proximal surgical margins, deceased prior to 12 months from index surgical intervention from non-DFO-related complications, underwent definitive above/below-knee amputation, or were without documented follow-up for chart review in EMR within 12 months from surgery by surgical, infectious disease, or primary care providers. Positive histopathology was defined by noted report of osteomyelitis and/or inflammation, or leukocyte infiltration of bone. Clinical care was typically arranged by treating services, including the interval and duration of follow-up after intervention.

Definitions and Variables

We defined treatment success as individuals not requiring further surgical amputation at the same site within a 12-month period from the index surgery. The primary analysis evaluated if there were differences in the rate of successful outcomes between the negative and positive proximal margin groups. Secondary analysis evaluated if there were differences in success rate based on microbiology (specifically Staphylococcus aureus), duration and route of antibiotic therapy, and readmission for surgical-site complications for non-amputation-related interventions at the index site (such as repeated incision and drainage, or revisions) the following 12 months from initial surgery.

A standard chart abstraction program was utilized to record data including demographics, duration and route of antimicrobial therapy, operative microbiology, histopathology results, methicillin-resistant S aureus (MRSA) screen on admission, history of prior non-infection-associated surgery at the same site, frequency of readmission after surgery for surgical complications, and if infectious disease was consulted during the amputation encounter. The most recent glycosylated hemoglobin (HbA1c) value within 3 months was recorded, with HbA1c further categorized into dichotomous categorical variable (≤7 vs <7%). The most current C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and procalcitonin were collected, either at admission or prior to surgery. Comorbidities such as vascular and microvascular disease and smoking history were recorded if ever documented in the EMR.

Statistical Analysis

Statistical analysis was performed by a biostatistician with the Comparative Effectiveness and Clinical Outcomes Research Center (CECORC) at our institution. Categorical variables were documented with absolute values and frequency, and continuous variables were documented with mean ± standard deviation. Categorical variables were analyzed as appropriate with χ2 analysis with a Bonferroni correction or Fisher exact test when applicable. Normally distributed continuous variables were analyzed using independent t test. Nonparametric continuous variables were analyzed using Mann-Whitney U test. Variables were then assessed for bivariate correlation with the outcome of interest and controlled for in a multivariate logistic regression model. Multivariable regression analysis was thus performed in assessing the 12 month outcomes of patients while controlling for covariates that were significantly correlated with the outcome and/or are clinically significant. Variables controlled for included age, sex, initial CRP levels, bone margin, HbA1c >7%, antibiotic class, course length, smoking history, and prevalence of a previous surgery. Furthermore, a time-to-event analysis was added to assess the 12-month failures. Cox regression analysis was utilized to demonstrate the correlation between bone margin and failure at the 12-month outcome adjusting for failures at time dropoffs earlier than 12 months. All data analysis was performed using SPSS version 26 software. P values <.05 were considered statistically significant.

RESULTS

A total of 697 patient cases from September 2016 through September 2019 were identified for review, with 271 cases identified as first-event DFO encounters. One hundred seventy-nine cases were excluded, and ultimately 92 cases were identified for the study population (Figure 1).

Study population flowchart. Abbreviations: DFO, diabetic foot osteomyelitis; EMR, electronic medical record; ICD-10, International Classification of Diseases, Tenth Revision.
Figure 1.

Study population flowchart. Abbreviations: DFO, diabetic foot osteomyelitis; EMR, electronic medical record; ICD-10, International Classification of Diseases, Tenth Revision.

Demographics and clinical characteristics of patients included in the study are noted in Table 1. Age, sex, and comorbidities including peripheral vascular disease and diabetic-associated microvascular disease (nephropathy, neuropathy, and retinopathy) were similar between the 2 groups.

Table 1.

Univariate Analysis of Population, Outcomes, Microbiology, and Antibiotic Characteristics

VariableNegative Margins
(n = 57)
Positive Margins
(n = 35)
P Value
Demographics and background
 Age, y, mean ± SD53 ± 1054 ± 10.66
 Male sex24 (73.7)30 (85.7).203
 HbA1c, %8.9 ± 2.78.3 ± 2.4.298
  ≤716 (28.1)15 (42.9).277
  >741 (71.9)20 (57.1).121
 Vascular disease24 (42.1)10 (28.6).192
 Smoking history20 (35.1)20 (57.1).038
 Prior surgery same site15 (26.3)13 (37.1).273
 Microvascular disease
 Neuropathy23 (40.4)15 (42.9).867
 Nephropathy17 (29.8)11 (31.4).914
 Retinopathy6 (10.5)4 (11.4).990
Laboratory results
 CRPa, mg/dL, mean ± SD10.17 ± 13.5413.0 ± 9.95.301
 ESRb, mm/h, mean ± SD88 ± 3192 ± 29.794
 Procalcitoninc, ng/mL, mean ± SD1.53 ± 3.721.9 ± 2.43.584
 MRSA screen0 (0.0)3 (8.6).004
Clostridioides difficile infection1 (1.8)0 (0.0).990
Microbiology of intraoperative surgical cultures
Staphylococcus aureusd17 (29.8)20 (57.1).017
  MSSA8 (14.0)16 (45.7).001
  MRSA9 (15.8)4 (11.4).399
Streptococcus spp only6 (10.5)4 (11.4).574
 Polymicrobial cultures without S aureus9 (15.8)3 (8.6).253
 Aerobic gram-negative rods onlye5 (8.8)2 (5.7).524
 Coagulase-negative Staphylococcus spp only2 (3.5)1 (2.9).990
 Negative cultures3 (5.3)1 (2.9).250
 No cultures collected15 (26.3)4 (11.4).272
Further organism breakdown of all polymicrobial operative cultures
 Anaerobes4 (7.0)0 (0.0).294
 Coagulase-negative
  Staphylococcus2 (3.5)2 (5.7).634
  Enterococcus spp6 (10.5)2 (5.7).706
  Enterobacter spp2 (3.5)1 (2.9).990
  Escherichia coli0 (0.0)2 (5.7).142
  Group B/G Streptococcus3 (5.3)9 (25.7).009
  Klebsiella pneumoniae0 (0.0)1 (2.9).380
  Proteus mirabilis2 (3.5)2 (5.7).634
  Pseudomonas aeruginosa4 (7.0)0 (0.0).294
  Providencia stuartii1 (1.8)0 (0.0).990
  Streptococcus viridans1 (1.8)0 (0.0).990
Outcomes
 Successful outcome at 12 mof49 (86.0)23 (65.7).033
 Successful outcome at 6 mof48 (84.2)24 (68.6).077
 Readmission after surgeryg15 (26.3)18 (51.4).015
Antibiotic characteristics
 Antibiotic duration, d, mean ± SD18 ± 1530 ± 15.001
 Antibiotic treatment
  Oral31 (54.4)12 (34.3).061
  Intravenous19 (33.3)23 (65.7).002
  Intravenous to oral1 (1.8)0 (0.0).062
  No antibiotics6 (10.5)0 (0.0).051
VariableNegative Margins
(n = 57)
Positive Margins
(n = 35)
P Value
Demographics and background
 Age, y, mean ± SD53 ± 1054 ± 10.66
 Male sex24 (73.7)30 (85.7).203
 HbA1c, %8.9 ± 2.78.3 ± 2.4.298
  ≤716 (28.1)15 (42.9).277
  >741 (71.9)20 (57.1).121
 Vascular disease24 (42.1)10 (28.6).192
 Smoking history20 (35.1)20 (57.1).038
 Prior surgery same site15 (26.3)13 (37.1).273
 Microvascular disease
 Neuropathy23 (40.4)15 (42.9).867
 Nephropathy17 (29.8)11 (31.4).914
 Retinopathy6 (10.5)4 (11.4).990
Laboratory results
 CRPa, mg/dL, mean ± SD10.17 ± 13.5413.0 ± 9.95.301
 ESRb, mm/h, mean ± SD88 ± 3192 ± 29.794
 Procalcitoninc, ng/mL, mean ± SD1.53 ± 3.721.9 ± 2.43.584
 MRSA screen0 (0.0)3 (8.6).004
Clostridioides difficile infection1 (1.8)0 (0.0).990
Microbiology of intraoperative surgical cultures
Staphylococcus aureusd17 (29.8)20 (57.1).017
  MSSA8 (14.0)16 (45.7).001
  MRSA9 (15.8)4 (11.4).399
Streptococcus spp only6 (10.5)4 (11.4).574
 Polymicrobial cultures without S aureus9 (15.8)3 (8.6).253
 Aerobic gram-negative rods onlye5 (8.8)2 (5.7).524
 Coagulase-negative Staphylococcus spp only2 (3.5)1 (2.9).990
 Negative cultures3 (5.3)1 (2.9).250
 No cultures collected15 (26.3)4 (11.4).272
Further organism breakdown of all polymicrobial operative cultures
 Anaerobes4 (7.0)0 (0.0).294
 Coagulase-negative
  Staphylococcus2 (3.5)2 (5.7).634
  Enterococcus spp6 (10.5)2 (5.7).706
  Enterobacter spp2 (3.5)1 (2.9).990
  Escherichia coli0 (0.0)2 (5.7).142
  Group B/G Streptococcus3 (5.3)9 (25.7).009
  Klebsiella pneumoniae0 (0.0)1 (2.9).380
  Proteus mirabilis2 (3.5)2 (5.7).634
  Pseudomonas aeruginosa4 (7.0)0 (0.0).294
  Providencia stuartii1 (1.8)0 (0.0).990
  Streptococcus viridans1 (1.8)0 (0.0).990
Outcomes
 Successful outcome at 12 mof49 (86.0)23 (65.7).033
 Successful outcome at 6 mof48 (84.2)24 (68.6).077
 Readmission after surgeryg15 (26.3)18 (51.4).015
Antibiotic characteristics
 Antibiotic duration, d, mean ± SD18 ± 1530 ± 15.001
 Antibiotic treatment
  Oral31 (54.4)12 (34.3).061
  Intravenous19 (33.3)23 (65.7).002
  Intravenous to oral1 (1.8)0 (0.0).062
  No antibiotics6 (10.5)0 (0.0).051

Data are presented as No. (%) unless otherwise indicated.

Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HbA1c, glycosylated hemoglobin; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; SD, standard deviation.

a

CRP reference range: 0–0.3 mg/dL.

b

ESR reference range: 0–20 mm/hour.

c

Procalcitonin reference range: 0.00–0.50 ng/mL.

d

Includes both monomicrobial and polymicrobial cultures with Staphylococcus aureus.

e

Escherichia coli (n = 5), Klebsiella spp (n = 1), Morganella morganii (n = 1), Proteus spp (n = 1), Pseudomonas aeruginosa (n = 1).

f

Not requiring further limb-sparing amputation at the same site.

g

Admission specifically related to complications of treatment site.

Table 1.

Univariate Analysis of Population, Outcomes, Microbiology, and Antibiotic Characteristics

VariableNegative Margins
(n = 57)
Positive Margins
(n = 35)
P Value
Demographics and background
 Age, y, mean ± SD53 ± 1054 ± 10.66
 Male sex24 (73.7)30 (85.7).203
 HbA1c, %8.9 ± 2.78.3 ± 2.4.298
  ≤716 (28.1)15 (42.9).277
  >741 (71.9)20 (57.1).121
 Vascular disease24 (42.1)10 (28.6).192
 Smoking history20 (35.1)20 (57.1).038
 Prior surgery same site15 (26.3)13 (37.1).273
 Microvascular disease
 Neuropathy23 (40.4)15 (42.9).867
 Nephropathy17 (29.8)11 (31.4).914
 Retinopathy6 (10.5)4 (11.4).990
Laboratory results
 CRPa, mg/dL, mean ± SD10.17 ± 13.5413.0 ± 9.95.301
 ESRb, mm/h, mean ± SD88 ± 3192 ± 29.794
 Procalcitoninc, ng/mL, mean ± SD1.53 ± 3.721.9 ± 2.43.584
 MRSA screen0 (0.0)3 (8.6).004
Clostridioides difficile infection1 (1.8)0 (0.0).990
Microbiology of intraoperative surgical cultures
Staphylococcus aureusd17 (29.8)20 (57.1).017
  MSSA8 (14.0)16 (45.7).001
  MRSA9 (15.8)4 (11.4).399
Streptococcus spp only6 (10.5)4 (11.4).574
 Polymicrobial cultures without S aureus9 (15.8)3 (8.6).253
 Aerobic gram-negative rods onlye5 (8.8)2 (5.7).524
 Coagulase-negative Staphylococcus spp only2 (3.5)1 (2.9).990
 Negative cultures3 (5.3)1 (2.9).250
 No cultures collected15 (26.3)4 (11.4).272
Further organism breakdown of all polymicrobial operative cultures
 Anaerobes4 (7.0)0 (0.0).294
 Coagulase-negative
  Staphylococcus2 (3.5)2 (5.7).634
  Enterococcus spp6 (10.5)2 (5.7).706
  Enterobacter spp2 (3.5)1 (2.9).990
  Escherichia coli0 (0.0)2 (5.7).142
  Group B/G Streptococcus3 (5.3)9 (25.7).009
  Klebsiella pneumoniae0 (0.0)1 (2.9).380
  Proteus mirabilis2 (3.5)2 (5.7).634
  Pseudomonas aeruginosa4 (7.0)0 (0.0).294
  Providencia stuartii1 (1.8)0 (0.0).990
  Streptococcus viridans1 (1.8)0 (0.0).990
Outcomes
 Successful outcome at 12 mof49 (86.0)23 (65.7).033
 Successful outcome at 6 mof48 (84.2)24 (68.6).077
 Readmission after surgeryg15 (26.3)18 (51.4).015
Antibiotic characteristics
 Antibiotic duration, d, mean ± SD18 ± 1530 ± 15.001
 Antibiotic treatment
  Oral31 (54.4)12 (34.3).061
  Intravenous19 (33.3)23 (65.7).002
  Intravenous to oral1 (1.8)0 (0.0).062
  No antibiotics6 (10.5)0 (0.0).051
VariableNegative Margins
(n = 57)
Positive Margins
(n = 35)
P Value
Demographics and background
 Age, y, mean ± SD53 ± 1054 ± 10.66
 Male sex24 (73.7)30 (85.7).203
 HbA1c, %8.9 ± 2.78.3 ± 2.4.298
  ≤716 (28.1)15 (42.9).277
  >741 (71.9)20 (57.1).121
 Vascular disease24 (42.1)10 (28.6).192
 Smoking history20 (35.1)20 (57.1).038
 Prior surgery same site15 (26.3)13 (37.1).273
 Microvascular disease
 Neuropathy23 (40.4)15 (42.9).867
 Nephropathy17 (29.8)11 (31.4).914
 Retinopathy6 (10.5)4 (11.4).990
Laboratory results
 CRPa, mg/dL, mean ± SD10.17 ± 13.5413.0 ± 9.95.301
 ESRb, mm/h, mean ± SD88 ± 3192 ± 29.794
 Procalcitoninc, ng/mL, mean ± SD1.53 ± 3.721.9 ± 2.43.584
 MRSA screen0 (0.0)3 (8.6).004
Clostridioides difficile infection1 (1.8)0 (0.0).990
Microbiology of intraoperative surgical cultures
Staphylococcus aureusd17 (29.8)20 (57.1).017
  MSSA8 (14.0)16 (45.7).001
  MRSA9 (15.8)4 (11.4).399
Streptococcus spp only6 (10.5)4 (11.4).574
 Polymicrobial cultures without S aureus9 (15.8)3 (8.6).253
 Aerobic gram-negative rods onlye5 (8.8)2 (5.7).524
 Coagulase-negative Staphylococcus spp only2 (3.5)1 (2.9).990
 Negative cultures3 (5.3)1 (2.9).250
 No cultures collected15 (26.3)4 (11.4).272
Further organism breakdown of all polymicrobial operative cultures
 Anaerobes4 (7.0)0 (0.0).294
 Coagulase-negative
  Staphylococcus2 (3.5)2 (5.7).634
  Enterococcus spp6 (10.5)2 (5.7).706
  Enterobacter spp2 (3.5)1 (2.9).990
  Escherichia coli0 (0.0)2 (5.7).142
  Group B/G Streptococcus3 (5.3)9 (25.7).009
  Klebsiella pneumoniae0 (0.0)1 (2.9).380
  Proteus mirabilis2 (3.5)2 (5.7).634
  Pseudomonas aeruginosa4 (7.0)0 (0.0).294
  Providencia stuartii1 (1.8)0 (0.0).990
  Streptococcus viridans1 (1.8)0 (0.0).990
Outcomes
 Successful outcome at 12 mof49 (86.0)23 (65.7).033
 Successful outcome at 6 mof48 (84.2)24 (68.6).077
 Readmission after surgeryg15 (26.3)18 (51.4).015
Antibiotic characteristics
 Antibiotic duration, d, mean ± SD18 ± 1530 ± 15.001
 Antibiotic treatment
  Oral31 (54.4)12 (34.3).061
  Intravenous19 (33.3)23 (65.7).002
  Intravenous to oral1 (1.8)0 (0.0).062
  No antibiotics6 (10.5)0 (0.0).051

Data are presented as No. (%) unless otherwise indicated.

Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HbA1c, glycosylated hemoglobin; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; SD, standard deviation.

a

CRP reference range: 0–0.3 mg/dL.

b

ESR reference range: 0–20 mm/hour.

c

Procalcitonin reference range: 0.00–0.50 ng/mL.

d

Includes both monomicrobial and polymicrobial cultures with Staphylococcus aureus.

e

Escherichia coli (n = 5), Klebsiella spp (n = 1), Morganella morganii (n = 1), Proteus spp (n = 1), Pseudomonas aeruginosa (n = 1).

f

Not requiring further limb-sparing amputation at the same site.

g

Admission specifically related to complications of treatment site.

Of the 92 cases, 57 had negative margins and 35 had positive margins. Forty-nine of 57 (86.0%) patients with negative margin resulted in a successful outcome compared to 23 of 35 (65.7%) in the positive-margin group. When comparing the 2 groups, this represented a statistically significant difference (86.0% vs 65.7%; P = .033) (Table 1). HbA1c was similar between the 2 groups (8.9% vs 8.3%; P = .298). HbA1c was not found to be significant with univariate or multivariate analysis. Furthermore, when controlling for HbA1c in the logistic regression model, no significant correlation was observed between HbA1c and incidences of failures at 12 months (Table 2). CRP, ESR, procalcitonin, and rates of Clostridioides difficile infection were not statistically different between the 2 groups. Frequency of infectious disease consultation did not differ between the 2 groups, but did trend higher toward the positive proximal margin group (Table 1). Among patient clinical characteristics, tobacco history was identified as the only characteristic with a statistically significant difference that was higher in the positive margin group (35.1% vs 57.1%; P = .038). On further multivariable regression analysis, tobacco history did not demonstrate a significant difference in success or failure at 12 months (Table 2).

Table 2.

Multivariable Analysis of Baseline Characteristics, Outcomes, Microbiology, and Antibiotic Characteristics Assessing 12-Month Failures

Independent VariableOR(95% CI)P Value
Bone margins (positive vs negative)5.091(1.26–20.571).022
Age, y0.994(.935–1.056).835
Sex1.799(.308–10.514).515
HbA1c >7% vs ≤7%1.283(.331–4.968).719
Smoking status0.943(.278–3.206).926
Initial CRP1.005(.963–1.05).806
Previous surgery at same site2.81(.836–9.452).095
Long vs short antibiotic course0.434(.093–2.028).289
Antibiotic treatment (IV vs PO)2.746(.615–12.271).186
Independent VariableOR(95% CI)P Value
Bone margins (positive vs negative)5.091(1.26–20.571).022
Age, y0.994(.935–1.056).835
Sex1.799(.308–10.514).515
HbA1c >7% vs ≤7%1.283(.331–4.968).719
Smoking status0.943(.278–3.206).926
Initial CRP1.005(.963–1.05).806
Previous surgery at same site2.81(.836–9.452).095
Long vs short antibiotic course0.434(.093–2.028).289
Antibiotic treatment (IV vs PO)2.746(.615–12.271).186

Abbreviations: CI, confidence interval; CRP, C-reactive protein; HbA1c, glycosylated hemoglobin; IV, intravenous; OR, odds ratio; PO, oral.

Table 2.

Multivariable Analysis of Baseline Characteristics, Outcomes, Microbiology, and Antibiotic Characteristics Assessing 12-Month Failures

Independent VariableOR(95% CI)P Value
Bone margins (positive vs negative)5.091(1.26–20.571).022
Age, y0.994(.935–1.056).835
Sex1.799(.308–10.514).515
HbA1c >7% vs ≤7%1.283(.331–4.968).719
Smoking status0.943(.278–3.206).926
Initial CRP1.005(.963–1.05).806
Previous surgery at same site2.81(.836–9.452).095
Long vs short antibiotic course0.434(.093–2.028).289
Antibiotic treatment (IV vs PO)2.746(.615–12.271).186
Independent VariableOR(95% CI)P Value
Bone margins (positive vs negative)5.091(1.26–20.571).022
Age, y0.994(.935–1.056).835
Sex1.799(.308–10.514).515
HbA1c >7% vs ≤7%1.283(.331–4.968).719
Smoking status0.943(.278–3.206).926
Initial CRP1.005(.963–1.05).806
Previous surgery at same site2.81(.836–9.452).095
Long vs short antibiotic course0.434(.093–2.028).289
Antibiotic treatment (IV vs PO)2.746(.615–12.271).186

Abbreviations: CI, confidence interval; CRP, C-reactive protein; HbA1c, glycosylated hemoglobin; IV, intravenous; OR, odds ratio; PO, oral.

Upon evaluating operative microbiology cultures, S aureus was noted more frequently in individuals with positive margins compared to negative margins (57.1% vs 29.8%; P = .017), with methicillin-susceptible S aureus being more predominant in those with positive margins (45.7% vs 14.0%; P = .001). MRSA rates were similar between the 2 groups (15.8% vs 11.4%; P = .399). Negative culture results were more notable in individuals with negative margins (43.9% vs 22.9%; P = .041) (Table 1). Operative cultures were not consistently documented directly from proximal margins, so could not be evaluated specifically in this context.

Readmission for surgical-site complications for non-amputation-related interventions at the index site within the following 12 months was also statistically different between the 2 groups with fewer readmissions in the negative-margin group (26.3% in negative-margin group vs 51.4% in positive-margin group; P = .015). Despite a statistically significant difference in successful outcomes at 12 months when comparing negative- to positive-margin groups, there was no observable difference between the 2 groups at 6 months, and did not achieve statistical significance (84.2% in negative-margin group vs 68.6% in positive-margin group; P = .077).

Antibiotic duration was significantly shorter in the negative-margin group with a mean duration of 18 ± 15 days versus 30 ± 15 days (P = .001; Table 1). Comparison of outcomes with intravenous versus oral antibiotics in multivariable analysis noted no significant differences in 12-month outcomes (odds ratio [OR], 2.746 [95% confidence interval {CI}, .615–12.271]; P = .186). These same findings were also observed in the logistic regression model in assessing 12-month outcomes (OR, 1.577 [95% CI, .461–5.397]; P = .468; Table 2).

In further multivariable regression analysis, only negative bone margins were significantly associated with higher rates of success at 12 months (Table 2). In adjusting for time-to-event analysis, again only negative margins were significantly associated with higher rates of success at 12 months. Other variables including diabetic control, antibiotic duration, and antibiotic type (oral vs intravenous therapy) were not found to be significantly associated with 12-month failures when adjusting for time-to-event analysis (Table 3).

Table 3.

Cox Regression Assessing 12-Month Failure (Adjusted for Time)

Independent VariableOR(95% CI)P Value
Bone margins (positive vs negative)3.282(1.103–9.766).033
Age, y0.987(.937–1.04).623
Sex1.882(.385–9.187).435
HbA1c >7% vs ≤7%1.214(.397–3.718).734
Smoking status0.944(.339–2.631).912
Initial CRP1.006(.972–1.041).741
Previous surgery at same site2.055(.807–5.231).131
Long versus short antibiotic course0.468(.126–1.741).257
Antibiotic treatment (IV vs PO)1.577(.461–5.397).468
Independent VariableOR(95% CI)P Value
Bone margins (positive vs negative)3.282(1.103–9.766).033
Age, y0.987(.937–1.04).623
Sex1.882(.385–9.187).435
HbA1c >7% vs ≤7%1.214(.397–3.718).734
Smoking status0.944(.339–2.631).912
Initial CRP1.006(.972–1.041).741
Previous surgery at same site2.055(.807–5.231).131
Long versus short antibiotic course0.468(.126–1.741).257
Antibiotic treatment (IV vs PO)1.577(.461–5.397).468

Abbreviations: CI, confidence interval; CRP, C-reactive protein; HbA1c, glycosylated hemoglobin; IV, intravenous; OR, odds ratio; PO, oral.

Table 3.

Cox Regression Assessing 12-Month Failure (Adjusted for Time)

Independent VariableOR(95% CI)P Value
Bone margins (positive vs negative)3.282(1.103–9.766).033
Age, y0.987(.937–1.04).623
Sex1.882(.385–9.187).435
HbA1c >7% vs ≤7%1.214(.397–3.718).734
Smoking status0.944(.339–2.631).912
Initial CRP1.006(.972–1.041).741
Previous surgery at same site2.055(.807–5.231).131
Long versus short antibiotic course0.468(.126–1.741).257
Antibiotic treatment (IV vs PO)1.577(.461–5.397).468
Independent VariableOR(95% CI)P Value
Bone margins (positive vs negative)3.282(1.103–9.766).033
Age, y0.987(.937–1.04).623
Sex1.882(.385–9.187).435
HbA1c >7% vs ≤7%1.214(.397–3.718).734
Smoking status0.944(.339–2.631).912
Initial CRP1.006(.972–1.041).741
Previous surgery at same site2.055(.807–5.231).131
Long versus short antibiotic course0.468(.126–1.741).257
Antibiotic treatment (IV vs PO)1.577(.461–5.397).468

Abbreviations: CI, confidence interval; CRP, C-reactive protein; HbA1c, glycosylated hemoglobin; IV, intravenous; OR, odds ratio; PO, oral.

Cumulative time-to-event analysis was performed and adjusted for all success and failure events by 12 months. All failure events occurred by 8 months from initial surgical intervention (Figure 2). Further evaluation specifically comparing failure events of negative to positive bone margins observed a higher success rate in negative-margin individuals (Figure 3).

Time-to-event analysis of cumulative 12-month success and failure.
Figure 2.

Time-to-event analysis of cumulative 12-month success and failure.

Time-to-event analysis of failures, stratified by proximal bone margin results.
Figure 3.

Time-to-event analysis of failures, stratified by proximal bone margin results.

DISCUSSION

In this study evaluating the outcomes of DFO requiring surgical amputation, individuals with negative proximal bone margins for osteomyelitis were observed to have less subsequent surgical amputation at the same site within the following 12 months. This was similar to observations and results in other studies [12, 13, 16]. Secondary analysis observed that patients with negative margins also had lower rates of readmission for surgical-site complications for non-amputation-related interventions at the same site over the following 12 months.

In evaluating antimicrobial therapy, negative histopathology for osteomyelitis at proximal margins was observed to result in shorter duration of antibiotics. In individuals with positive margin, the mean treatment duration was 30 days (±15 days), but despite receiving less than the full 6 weeks of therapy on average, 65.7% of positive margin cases still had successful outcomes. Definitive conclusions could not be drawn regarding the appropriateness and outcome of shorter antimicrobial courses for individuals with positive margins, and future studies should evaluate if shorter durations of antibiotics than the typical 6-week course is a viable option in these presentations. The utilization of bone margins results could be considered in stewardship interventions directed toward optimizing duration of antimicrobial therapy [17].

Further observations of 12-month success between individuals receiving intravenous versus oral antibiotics noted no differences. This study noted only 1 instance of an individual who transitioned from intravenous to oral therapy, which had a successful outcome. No individuals switched from oral to intravenous antibiotics. This may further support the emerging evidence for utilizing or transitioning from intravenous to oral antibiotics for definitive therapy, potentially leading to lower complications and costs [18, 19].

Staphylococcus aureus was the most common organism documented in the study, consistent with prior epidemiology reports [20]. When evaluating if there was a difference in successful outcomes regardless of proximal margin results in the presence of S aureus, there were no observed differences. Yet the presence of S aureus was significantly higher in positive margins, which were observed to have more failure rates. The presence of S aureus with positive margins may warrant a more aggressive approach given the significant correlation with positive margins and poorer outcomes, but this study was not able to draw a definitive observation regarding this point, and further studies would need to be conducted. Interestingly when evaluating the overall microbiology of the 20 failure cases needing repeat surgical amputation by 12 months, only 2 had the same microbiology on repeat operative cultures, none which were S aureus.

Strengths of this study included the relevancy to our specific patient population at a safety-net county hospital where there can be barriers for access to care. There were several limitations with this study. First was the retrospective design with a relatively small sample size. Furthermore, given the single-center location and specific patient population unique to our center, the results may not be applicable to other populations. The study specifically identified the need for further surgical amputation at the same site within a 12-month period as the criteria for treatment success or failure, but persistent nonhealing wound at the surgical site, which is a frequent sign of delayed recovery, was not categorized as a treatment failure. A significant portion of identified cases also had to be excluded (179 of 271 unique encounters), with most of them due to deficient histopathology documentation of proximal margins, or inconclusive EMR documentation records through 12 months. These individuals may have been lost to the system, established care elsewhere, or not needed further follow-up due to complete clinical resolution of infection, and thus were not accounted for in this review. Regarding differences in outcomes of individuals with histopathology versus the lack of histopathology, this was not specifically evaluated and would require further studies. Although there were no differences in outcomes when comparing oral versus intravenous antibiotics, the choice was not based on a preset guideline and was physician dependent, so this potentially introduced bias into the results. Comorbid tobacco use, which is commonly known to lead to poor wound healing in general and in DFIs, was significantly more prevalent in the positive-margin group, and this may represent a potential confounding factor [21, 22]. However, further multivariate analysis did not observe a statistically significant difference in our results.

CONCLUSIONS

In summary, our results observed that patients with negative proximal surgical resected bone margins after limb-sparing amputations in DFO lead to more successful outcomes and required less subsequent amputations at the same site by 12 months. Individuals with negative margins were observed to receive shorter courses of antimicrobial therapy. The route of antimicrobial administration did not affect primary outcomes. Proximal margin results potentially can be integrated to help predict outcomes and guide antimicrobial duration usage. Further studies are needed to evaluate the ongoing debate surrounding the clinical relevance of proximal surgical resected bone margins in DFO, along with optimal antimicrobial duration in these cases.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes

Acknowledgments. The authors thank Hien Huy Nguyen, MD; Rebecca Moellmer, DPM; Adrienne Estes, DPM; and Nikita Patel, PharmD for their contributions to the development of this study.

Financial support. There was no external funding for this study.

Patient consent. The study was approved by the local institutional review board and granted a waiver for consent due to the retrospective design.

The authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1

Centers for Disease Control and Prevention (CDC)
.
National diabetes statistics report, 2020. Atlanta, GA: CDC
;
2020
.

2

Care
D
.
Economic costs of diabetes in the US in 2017
.
Diabetes Care
2018
;
41
:
917
28
.

3

Acharya
S
,
Soliman
M
,
Egun
A
, et al.
Conservative management of diabetic foot osteomyelitis
.
Diabetes Res Clin Pract
2013
;
101
:
e18
20
.

4

Peters
EJ
,
Lipsky
BA
,
Aragón-Sánchez
J
, et al.
Interventions in the management of infection in the foot in diabetes: a systematic review
.
Diabetes Metab Res Rev
2016
;
32
:
145
53
.

5

Jeffcoate
WJ
,
Lipsky
BA
.
Controversies in diagnosing and managing osteomyelitis of the foot in diabetes
.
Clin Infect Dis
2004
;
39
(
Suppl 2
):
S115
22
.

6

Henke
PK
,
Blackburn
SA
,
Wainess
RW
, et al.
Osteomyelitis of the foot and toe in adults is a surgical disease: conservative management worsens lower extremity salvage
.
Ann Surg
2005
;
241
:
885
94
.

7

Lipsky
BA
,
Berendt
AR
,
Cornia
PB
, et al.
2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections
.
Clin Infect Dis
2012
;
54
:
e132
73
.

8

Lipsky
BA
,
Aragón-Sánchez
J
,
Diggle
M
, et al.
International Working Group on the Diabetic Foot. IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes
.
Diabetes Metab Res Rev
2016
;
32
:
45
74
.

9

Lee
E
,
Pupaibool
J
,
Certain
L
.
188. The role of bone pathology in the management of residual osteomyelitis after amputation for diabetic foot infections
.
Open Forum Infect Dis
2020
;
7
(
Suppl 1
):
S222
3
.

10

Dixon
MK
,
Cadena
J
,
Walter
E
.
Comparing outcomes of diabetic foot infections requiring amputation, negative vs. positive margins
.
Open Forum Infect Dis
2019
;
6
(
Suppl 2
):
S521
.

11

Johnson
MJ
,
Shumway
N
,
Bivins
M
, et al.
Outcomes of limb-sparing surgery for osteomyelitis in the diabetic foot: importance of the histopathologic margin
.
Open Forum Infect Dis
2019
;
6
:
ofz382
.

12

Kowalski
TJ
,
Matsuda
M
,
Sorenson
MD
, et al.
The effect of residual osteomyelitis at the resection margin in patients with surgically treated diabetic foot infection
.
J Foot Ankle Surg
2011
;
50
:
171
5
.

13

Simpson
AH
,
Deakin
M
,
Latham
JM
.
Chronic osteomyelitis: the effect of the extent of surgical resection on infection-free survival
.
J Bone Joint Surg Br
2001
;
83
:
403
7
.

14

Beieler
AM
,
Jenkins
TC
,
Price
CS
, et al.
Successful limb-sparing treatment strategy for diabetic foot osteomyelitis
.
J Am Podiatr Med Assoc
2012
;
102
:
273
7
.

15

Barshes
NR
,
Mindru
C
,
Ashong
C
, et al.
Treatment failure and leg amputation among patients with foot osteomyelitis
.
Int J Low Extrem Wounds
2016
;
15
:
303
12
.

16

Atway
S
,
Nerone
VS
,
Springer
KD
, et al.
Rate of residual osteomyelitis after partial foot amputation in diabetic patients: a standardized method for evaluating bone margins with intraoperative culture
.
J Foot Ankle Surg
2012
;
51
:
749
52
.

17

Lipsky
BA
,
Uçkay
İ
.
Treating diabetic foot osteomyelitis: a practical state-of-the-art update
.
Medicina (Kaunas)
2021
;
57
:
339
.

18

Li
HK
,
Rombach
I
,
Zambellas
R
, et al.
Oral versus intravenous antibiotics for bone and joint infection
.
N Engl J Med
2019
;
380
:
425
36
.

19

Gariani
K
,
Lebowitz
D
,
Kressmann
B
, et al.
Oral amoxicillin-clavulanate for treating diabetic foot infections.
Diabetes Obes Metab
2019
;
21
:
1483
6
.

20

Giurato
L
,
Meloni
M
,
Izzo
V
, et al.
Osteomyelitis in diabetic foot: a comprehensive overview
.
World J Diabetes
2017
;
8
:
135
.

21

Silverstein
P
.
Smoking and wound healing
.
Am J Med
1992
;
93
:
S22
4
.

22

Liu
M
,
Zhang
W
,
Yan
Z
, et al.
Smoking increases the risk of diabetic foot amputation: a meta-analysis
.
Exp Ther Med
2018
;
15
:
1680
5
.

Author notes

Potential conflicts of interest. All authors: No reported conflicts.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [email protected]

Supplementary data

Comments

0 Comments
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.